Fourth quarter 2025 reported sales decreased 3.7% to $2 billion, while organic sales increased 3.5%. Full-year 2025 reported sales increased 0.9% to $8.325 billion, with organic sales growth of 3.3%. GAAP diluted earnings per share for Q4 2025 was $0.36, and adjusted diluted earnings per share was $1.57. Full-year 2025 GAAP diluted earnings per share was $8.88, and adjusted diluted earnings per share was $6.11. Operating cash flow for Q4 2025 was $96 million; free cash flow was $33 million. Full-year 2025 operating cash flow was $369 million; free cash flow was negative $10 million. All segments demonstrated positive organic sales growth in Q4, primarily driven by Infection Prevention and Surgical Solutions and Dental Solutions. For full-year 2026, Solventum guides for organic sales growth of +2.0% to +3.0% (or +3.0% to +4.0% excluding ~100bps SKU exit impact), adjusted EPS of $6.40 to $6.60, and free cash flow of ~$200 million.